Cargando…
Ebastine impairs metastatic spread in triple-negative breast cancer by targeting focal adhesion kinase
We sought to investigate the utility of ebastine (EBA), a second-generation antihistamine with potent anti-metastatic properties, in the context of breast cancer stem cell (BCSC)-suppression in triple-negative breast cancer (TNBC). EBA binds to the tyrosine kinase domain of focal adhesion kinase (FA...
Autores principales: | Seo, Juyeon, Park, Minsu, Ko, Dongmi, Kim, Seongjae, Park, Jung Min, Park, Soeun, Nam, Kee Dal, Farrand, Lee, Yang, Jinsol, Seok, Chaok, Jung, Eunsun, Kim, Yoon-Jae, Kim, Ji Young, Seo, Jae Hong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10130003/ https://www.ncbi.nlm.nih.gov/pubmed/37185776 http://dx.doi.org/10.1007/s00018-023-04760-5 |
Ejemplares similares
-
β-Escin overcomes trastuzumab resistance in HER2-positive breast cancer by targeting cancer stem-like features
por: Park, Soeun, et al.
Publicado: (2022) -
Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR
por: Kim, Seongjae, et al.
Publicado: (2023) -
A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response
por: Kim, Ji Young, et al.
Publicado: (2022) -
The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells
por: Park, Soeun, et al.
Publicado: (2021) -
A novel HSP90 inhibitor targeting the C-terminal domain attenuates trastuzumab resistance in HER2-positive breast cancer
por: Park, Jung Min, et al.
Publicado: (2020)